Jubilant Pharmova Limited

Total Valuation

Jubilant Pharmova Limited carries a market capitalization of 156.22B, placing it among publicly traded companies globally. Its enterprise value stands at 191.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

Jubilant Pharmova Limited trades at a trailing price-to-earnings ratio of 41.65.

Enterprise Valuation

On an enterprise value basis, Jubilant Pharmova Limited trades at an EV/EBITDA multiple of 22.93 and an EV/FCF ratio of 122.05. The EV/Sales ratio of 2.61 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 22.93 provides insight into valuation relative to core operating earnings.

Financial Position

Jubilant Pharmova Limited maintains a current ratio of 3.45, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 95.75, indicating elevated leverage, while an interest coverage ratio of 3.83 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Jubilant Pharmova Limited has paid 1.78B in income taxes, reflecting an effective tax rate of 28.07.

Stock Price Statistics

Jubilant Pharmova Limited's stock has declined approximately -17.83556% over the past 52 weeks. The 50-day moving average sits at 975.53, while the 200-day moving average is 995.44.

Income Statement

Over the trailing twelve months, Jubilant Pharmova Limited generated 73.51B in revenue and converted that into 4.60B in net income, yielding earnings per share of 28.76. EBITDA reached 8.36B, while operating income came in at 8.36B.

Margins

Jubilant Pharmova Limited operates with a gross margin of 67.71, reflecting its pricing power and cost economics. The operating margin of 11.37 and net profit margin of 6.26 provide insight into operational efficiency.

Stock Splits

Jubilant Pharmova Limited's most recent stock split took place on March 17, 2006 with a 1:5 split ratio.

Scores

Jubilant Pharmova Limited posts an Altman Z-Score of 6.51, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.